CERE Insider Trading

Notice: This stock is marked as potentially delisted. It may not be actively trading.
Insider Ownership Percentage: 5.10%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $3,134,500.00

Cerevel Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Cerevel Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$100M$0$100MTotal Insider BuyingTotal Insider Selling

Cerevel Therapeutics Share Price & Price History

Current Price: $44.96
Price Change: +0.30 (1.20%)
As of 08/1/2024 01:00 AM ET

This chart shows the closing price history over time for CERE up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table

SEC Filings (Institutional Ownership Changes) for Cerevel Therapeutics (NASDAQ:CERE)

87.73% of Cerevel Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at CERE by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
202220232024$0bought$58MsoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4-$1B-$500M$0$500M$1BTotal InflowsTotal Outflows
Cerevel Therapeutics logo
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States. It is developing Emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures or focal epilepsy, as well as in phase 1 trial to treat panic symptoms model. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist, which is in Phase 2a clinical trial to treat dementia-related apathy; and CVL-354, a selective kappa-opioid receptor antagonist to treat major depressive disorder and substance use disorder. It is also involved in the development of an M4 agonist program for the treatment of psychosis and related indications; and PDE4 inhibitor for the treatment of psychiatric, neuroinflammatory, and other disorders. Cerevel Therapeutics Holdings, Inc. was founded in 2018 and is headquartered in Cambridge, Massachusetts.
Read More on Cerevel Therapeutics

Today's Range

Now: $44.96
Low: $44.96
High: $44.96

50 Day Range

MA: $43.67
Low: $40.30
High: $44.96

52 Week Range

Now: $44.96
Low: $19.59
High: $44.99

Volume

N/A

Average Volume

1,709,788 shs

Market Capitalization

$8.19 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.4

Who are the company insiders with the largest holdings of Cerevel Therapeutics?

Cerevel Therapeutics' top insider investors include:
  1. Bain Capital Investors Llc (Major Shareholder)
  2. Perceptive Advisors Llc (Director)
  3. Marijn E Dekkers (Director)
  4. Ronald C Renaud Jr (CEO)
  5. N Anthony Coles (Director)
  6. Kenneth Dipietro (Insider)
  7. Paul D Burgess (Insider)
  8. Mark Bodenrader (Insider)
  9. Susan Altschuller (CFO)
  10. Ramiro Sanchez (Insider)
  11. John Renger (Insider)
  12. N Anthony Coles (CEO)
  13. Scott Akamine (Insider)
Learn More about top insider investors at Cerevel Therapeutics.